Category REGENERATIVE MEDICINE

Hopkins team invents non-viral system for getting gene therapy into cells

Polymer-based nanocontainers could improve the delivery of gene therapies, a Johns Hopkins team reported. One of the most popular methods for inserting therapeutic genes into cells to treat disease is to transport them using a virus that has been stripped of its infectious properties. But those noninfectious viruses can still sometimes touch off dangerous immune

Read More


Stanford researchers program cancer-fighting cells to resist exhaustion, attack solid tumors in mice

CAR-T cells are remarkably effective against blood cancers, but their effect can be transient as the cells become exhausted. Stanford researchers found a way to keep the cells effective in mice with human tumors. A new approach to programming cancer-fighting immune cells called CAR-T cells can prolong their activity and increase their effectiveness against human

Read More


Mesenchymal stem cell perspective: cell biology to clinical progress. Review

The terms MSC and MSCs have become the preferred acronym to describe a cell and a cell population of multipotential stem/ progenitor cells commonly referred to as mesenchymal stem cells, multipotential stromal cells, mesenchymal stromal cells, and mesenchymal progenitor cells. The MSCs can differentiate to important lineages under defined conditions in vitro and in limited

Read More


Novartis’ new cell therapy facility could ease manufacturing squeeze for CAR-T med Kymriah

Novartis’ big push into cell and gene therapy hasn’t been the smoothest of rides, with a data manipulation scandal hamstringing Zolgensma and manufacturing concerns hurting CAR-T cancer therapy Kymriah. Could a new European facility help turn around the latter’s production bottleneck?  Novartis last week opened its newest cell and gene therapy facility in Stein, Switzerland, giving the

Read More


Pfizer, Novartis lead $2 billion spending spree on gene therapy production

Source REUTERS Eleven drugmakers led by Pfizer and Novartis have set aside a combined $2 billion to invest in gene therapy manufacturing since 2018, according to a Reuters analysis, in a drive to better control production of the world’s priciest medicines. The full scope of Novartis’ $500 million plan, revealed to Reuters in an interview

Read More


Mitochondria–Lysosome Crosstalk: From Physiology to Neurodegeneration

Source Trends in Molecular Medicine Mitochondria and lysosomes are pivotal organelles for cellular metabolism and also have important roles as signaling platforms. Many diseases are characterized by impaired mitochondrial or lysosomal function. These are often referred to as ‘mitochondrial diseases’, which have a primary cause in mitochondria, or as lysosomal storage diseases. Although each specific

Read More


Wyss Institute researchers demonstrate machine-guided engineering of AAV capsids for gene therapy

High-throughput synthetic biology approach reveals hidden AAV features and could help fast-track future gene therapies Adeno-associated viruses (AAVs) have become the go-to vehicle for delivering therapeutic gene cargo to target tissues for the wave of gene therapies that are in development in academic and biotechnology laboratories. However, natural AAVs do not specifically target diseased cells

Read More


BIOLOGICS ALLIANCE™ INITIATES COLLABORATION WITHIN ORTHOPAEDICS COMMUNITY

For the first time, The Arthroscopy Association of North America (AANA), the American Orthopaedic Society for Sports Medicine (AOSSM), the International Cartilage Repair Society (ICRS) and the ON Foundation have collaborated to form The Biologics Alliance (BA)™, an orthopaedic organization dedicated to providing one voice for all matters on musculoskeletal biologics and regenerative medicine. Recently, randomized clinical trials and clinical practice guidelines

Read More